A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the HARMONY study is to assess the safety and efficacy of an investigational
drug called HuZAF, in patients with moderate to severe Crohn's disease (CD). HuZAF is a
humanized anti-Interferon-gamma (anti-IFN-γ) monoclonal antibody, which binds and blocks
IFN-γ, a protein in the immune system that is involved in inflammation. Antibodies are
proteins normally produced by our immune system to help fight off foreign substances.
Scientists have been able to make therapeutic humanized monoclonal antibodies, similar to the
antibodies in our bodies, to target diseases.